A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
Study sponsor: Glaukos Corporation
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-12Estimated
Enrollment · participants84Estimated
Source updated2025-07-24Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.